Vega Therapeutics

Name

Vega Therapeutics

Legal name

Vega Therapeutics, Inc.

Website

https://vega-therapeutics.com

Company type

Private

Founded year

2018

Operating status

Acquired

Headcount range

11–50 employees

Ownership category

akta.pro rank

Product category

Rare Disease Biologics

NAICS

Biological Product (except Diagnostic) Manufacturing (325414)

SIC

Biological Products, (No Disgnostic Substances) (2836)

akta.pro primary industry

Monoclonal Antibody Therapeutics (mAbs) (HLAAAAAA)

akta.pro secondary industry

Regulatory Strategy & IND/NDA/BLA Submissions Support (HLAIALAH)

Keywords

• Monoclonal antibody therapy
• Rare disease therapeutics
• Bleeding disorder treatment
• Subcutaneous biologic therapy
• Biopharmaceutical drug development

Headquarters

HQ city

South San Francisco

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations

Revenue model

1. Pharmaceutical Product Revenue: Vega Therapeutics is a clinical-stage biotech company with no commercialized products. Revenue will come from sales of VGA039 upon regulatory approval. The company was acquired by Incyte Corporation for up to $2 billion, with $1.25 billion upfront and up to $750 million in sales milestones.

Core offering

Vega Therapeutics develops VGA039, a first-in-class monoclonal antibody that targets Protein S (PROS1) to rebalance coagulation in patients with von Willebrand disease. The asset is in Phase 3 clinical development (VIVID trial) and is designed as a once-monthly subcutaneous prophylactic therapy intended for all VWD subtypes. The company operates as a wholly owned subsidiary of Star Therapeutics and is being acquired by Incyte Corporation.

Product overview

Vega Therapeutics, a wholly owned subsidiary of Star Therapeutics, is developing the VEGA Program focused on bleeding disorders, starting with VGA039. VGA039 is a first-in-class Protein S-targeting monoclonal antibody in Phase 3 development for von Willebrand disease (VWD). The therapy is being studied in the VIVID multistage clinical trial and has received FDA Fast Track, Orphan Drug, Rare Pediatric Disease, and Breakthrough Therapy designations. VGA039 has the potential to be the first subcutaneous prophylactic treatment for all types of VWD with once-monthly dosing, offering a significant improvement over current treatments that require frequent intravenous infusions.

Differentiator

Problem solved

Functional benefit

Brands

• VEGA Program: A program under Star Therapeutics focused on bringing overlooked needs into focus for patients with bleeding disorders, starting with von Willebrand disease (VWD). The VEGA Program encompasses VGA039, a subcutaneously administered monoclonal antibody therapy.

Products and services

• VGA039

Quantifiable outcome

• 81% median bleed reduction in early-phase studies
• +2 more outcomes

Segments1 record

Ideal customer profiles1 record

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature1 record

Partnerships

Two partnerships are on record, tiered core.

• Incyte CorporationcoreStrategic or Co-development Partner · 8 June 2026Incyte announced a definitive agreement to acquire Vega Therapeutics, Inc., a wholly owned subsidiary of Star Therapeutics, for $1.25 billion upfront plus up to $750 million in sales milestones, totaling up to $2.0 billion in potential consideration. The acquisition adds VGA039 to Incyte's hematology portfolio. The transaction was approved by both boards and expected to close in Q3 2026 pending Hart-Scott-Rodino review.
• Star TherapeuticscoreStrategic or Co-development PartnerVega Therapeutics is a wholly owned subsidiary of Star Therapeutics (LLC). Star Therapeutics operates the VEGA Program focused on bringing solutions for patients with bleeding disorders, starting with VWD. Star is headquartered at 201 Haskins Way, 5th Floor, South San Francisco, CA 94080.

Scale indicators5 records

Recent moves5 records

Expansion highlights4 records

Broad incumbents

• Pfizer: Pfizer partners with Sobi on hemophilia therapies (e.g., BeneFIX, ReFacto) and has broader hematology commercial reach, making it a relevant incumbent comparator for prophylactic bleeding-disorder commercialization.
• CSL Behring: CSL Behring is a major plasma-derived therapies company with a broad hematology portfolio including VWD products (e.g., Humate-P/Wilate), overlapping with Vega's bleeding-disorder therapeutic area and commercial channels.
• Octapharma: Octapharma markets Wilate (plasma-derived VWF/FVIII) for von Willebrand disease, a direct in-class incumbent comparable to VGA039's target indication and patient population.
• Sanofi (Genzyme/Sobi-acquired portfolio): Sanofi, via its Bioverativ/Sobi-originated hemophilia franchise (Eloctate, Altuviiio), is a broad incumbent in the bleeding-disorder market and a potential comparator for VWD prophylaxis positioning.
• Roche: Roche's Hemlibra (emicizumab) is a leading subcutaneous mAb for hemophilia A and a relevant peer for subcutaneous antibody-based prophylaxis in bleeding disorders, including for competitive commercial benchmark.
• Takeda Pharmaceutical: Takeda's hematology franchise (Adynovate/Adynovi and other coagulation products) targets bleeding disorders including hemophilia and VWD, making it a broad incumbent with overlapping patient reach and competing prophylactic options.

Direct peers

• BioMarin Pharmaceutical: BioMarin markets Vonvendi (recombinant von Willebrand factor) for VWD, the most direct in-market competitor to VGA039 in the same patient population and indication, with established hematology commercial infrastructure.

Emerging players

• Alnylam Pharmaceuticals: Alnylam develops RNAi-based therapeutics including programs relevant to coagulation and hematology, representing an emerging modality with partial overlap in mechanism novelty for bleeding disorders.
• uniQure: uniQure is advancing AAV-based gene therapy for hemophilia B and exploring other coagulation disorders — a partial-overlap emerging modality that could compete with chronic mAb prophylaxis in the same patient universe.
• Catalyst Biosciences: Catalyst Biosciences is a smaller clinical-stage company developing engineered coagulation factors (e.g., marzeptacog alfa for hemophilia) — an emerging peer with adjacent bleeding-disorder focus but a different mechanism.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat3 records

Key risks6 records

Key highlights6 records

Customer concentration

• LinkedInlinkedin.com/company/vega-therapeutics

Compliance4 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Funding overview

Funding rounds1 record

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Vega Therapeutics